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Summary: The purpose of these studies was to develop a high performance liquid Chromatographie (HPLC)
assay for plasma levels of indomethacin. A reversed phase (C18 Sep-Pak) cartridge was used to process
plasma for absorption of indomethacin, the internal Standard, and impurities. The recovery of plasma
indomethacin and the added internal Standard was quantitative from 0.5 ml of plasma. The assay was linear
from 50 g/l to 10 mg/1 without concentration of the effluent from the Sep-Pak cartridge. The intra-assay
coefficients of Variation, for ten injections each to calibrate points at 0.15, 0.30, 0.50 and 1.00 mg/1, were
8.15%, 6.29%, 5.47% and 5.39%, respectively and for duplicates of duplicate calibration points were 7.51%,
6.32%, 4.41%, and 2.05%, respectively. The inter-assay coefficients of Variation were 8.49%, 6.48%, 5.10%,
and 2.22%, respectively. The sensitivity of the assay can be increased by a 3 —5 fold concentration of the
effluent from the Sep-Pak and preliminary experiments have indicated that äs little äs 100 of starting
plasma can be utilized in the assay.
The assay can be used to determine the concentration of indomethacin in small volumes of plasma. Since
Cig Sep-Pak cartridges were employed to remove contaminating substances, sensitivity and reproducibility
were both high while column longevity and efficiency were excellent.
Die Verwendung von Reversed Phase-Patronen (C1S) för die Aufarbeitung von Plasma zur Analyse von
Indomethacin durch Hochleistuhgsflüssigchromatographie
Zusammenfassung: Eine hochleistungsffüssigchromatographische Methode zur Bestimmung von Indometha-
cin im Plasma wird vorgestellt. Zur Absorption von Indomethacin, internem Standard und Verunreinigungen
wurde eine Reversed Phase (Ci8Sep-Pak)-Patrone verwendet. Die Wiederfindung von Indomethacin und dem
hinzugefügten internen Standard war aus 0,5 ml Plasma quantitativ. Die Methode ist ohne Konzentrierung
des Effluent aus der Sep-Pak-Patrone von 50 g/l bis 10 mg/1 linear. Die Variationskoeffizienten in der Serie
betrugen für 10 Injektionen zujedef Kalibratorkonzentration von 0,15, 0,30, 0,50 und 1,00 mg/1 8,15, 6,29,
5,47 und 2,05%, für Doppelbestimmungen von jeweils zwei Lösungen jeder Kalibratorkonzentration 7,51,
6,32, 4,41 und 2,05%. Die Variationskoeffizienten von Serie zu S~erie betrugen 8,49, 6,48, 5,10 und 2,22%.
Die Empfindlichkeit der Methode kann durch 3 — Sfache Konzentrierung des Effluent der Sep-Pak-Patrone
gesteigert werden; Vorversuche ergaben, daß nur 100 Plasma als Ausgangsmaterial für die Bestimmung
ausreichen.
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Die Methode kann zur Bestimmung von Indomethacin in kleinen Plasmavolumina angewandt werden. Da
C|8 Sep-Pak-Patronen zur Entfernung von Begleitsubstanzen angewandt werden, sind Empfindlichkeit und
Reproduzierbarkeit hoch, dabei Langlebigkeit und Wirksamkeit hervorragend.
Introduction
Indomethacin, a hydroxyindole derivative which in-
hibits the enzyme cyclo-oxygenase found in endothe-
lial cells and platelets, is used to treat pre-term infants
with patent ductus arteriosus in order to effect closure
(l — 5). Use of the medication is limited by its undesir-
able effects which include Inhibition of platelet aggre-
gation (6), decreased renal water clearance (7—10)
and displacement of protein bound circulating biliru-
bin (11,12). A rapid, reliable method for quantitation
of plasma indomethacin would aid in determination
of therapeutically effective levels for minimizing do-
sage of administered drug. The ususal method of
processing serum or plasma is to precipitate protein,
extract both the indomethacin and internal Standard
with an organic solvent, then concentrate and assay
for indomethacin by a variety of methods (13—27).
We established a high performance liquid chromato-
graphy (HPLC) assay for indomethacin in human
plasma by a method previously reported for rabbit
plasma (20). However, limited reproducibilty, sub-
optimal column efficiency and decreased column life
occurred despite frequent column cleaning during our
studies. These problems were related to residue from
processed plasma samples. Therefore, we investigated
the use of reversed phase (Qg Sep-Pak) cartridges for
processing plasma samples before HPLC analysis of
indomethacin. This Step allowed excellent reproduc-
ibility in the quantitation of indomethacin and mark-




All solvents, including those used for sample preparation, were
HPLC grade. Chemicals were of the highest purity available
and purchased from either Fisher Scientific or American Scien-
tific Products. All reagents were filtered through 0.22 μιη Milli-
pore filters and degassed before use. The indomethacin and the
internal Standard l-0?-fluorobenzoyl)-5-methoxy-2-methylin-
dole acetic acid were obtained from Dr. Morton Rosenberg
and Dr. Clement Stone (Merck, Sharp and Dohme Research
Laboratories). The Sep-Pak C18 cartridges (three different lot
nurabers) were purchased from Waters Inc.
A Beckman HPLC model 344 with two 112 pumps and a
model 421 Controller was used for analysis of samples. The
components of the processed plasma samples were separated
using a C18 Ultrasphere ODS Reversed Phase Column (4.6 mm
χ 150 mm, Beckman) and a Precolumn (4.6 mm χ 25 mm,
Beckman) each packed with 5 μιη particles. A 20 μΐ sample
injector loop was used with a model 160 absorbance detector
(Beckman) at 254 nm. A strip chait reoorder (Kipp and Zonen)
was used for peak height concentration while an integr tor
(Spectra-Physics SP4270) with the following settings was used
to quantitate areas: Chart Speed (CS) == l cm/min; Peak Width
(PW) = 18; Peak Threshold (PT) = 25; Integrate Inhibit (II)
= 1; Disable Tailing Peak Logic (TP) = l (off); Attenuation
(AT) for chart = 8 at 0.1 min; Attenuation (AT) for chart = 4
at 4.5 min; Peak Markers (PM) = l (On) at 4.5 min; Integrate
Inhibit (II) = 0 (start Integration) at 4.5 min; End Run (ER)
= l at 9.5 min.
Method
Plasma for the c libration curve and from study subjects was
prepared by collecting blood in Venoject tubes (Terumo Medical
Corp.) containing liquid potassium EDTA and potassium sor-
bate. Tubes were placed on wet ice and immediately subjected
to centrifugation at 1200 g for 10 minutes at 4 °C. Supernatahts
were divided into aliquots and stored at —70 °C until used for
c libration curves or analyzed for indomethacin levels.
Indomethacin stock solution was prepared by dissolving 1.25
mg in a total of 5.00 ml methanol (final 250 mg/1) and then
storing at —70 °C. A daily stock solution was prepared by
diluting 50 μΐ of the freezer stock to 5.00 ml with methanol
(final stock concentration 2.5 mg/1) and then storing at 4 °C.
Internal Standard stock solution was prepared in the same
manner s the indomethacin to btain a concentration of 250
mg/1 and stored at — 70 °C. For the daily stock, 200 μΐ was
diluted to 5.00 ml with methanol (final concentration of 10
mg/1).
For preparation of the c libration curve, the following proce-
dure was used: 1.0 μg of internal Standard (100 μΐ of 10 mg/1
stock) was added to 0.5 ml of plasma and then 0.50 μg, 0.25
μ& 0.15 μg or 0.075 μg (200«.uk 100 ul, 60 μΐ and 30 μΐ,
respectively of 250 mg/1 stock) of indomethacin were added.
Each of the four calibration curve samples was prepared in
duplicate. The patient samples and calibration curve samples
were processed identically and simultanepusly.
After addition of the internal Standard and indomethacin, the
volume of each tube was diluted tq exactly 2.5 ml with methanol
in H2 , volume fraction 0.75. The mixture was agitated on a
vortex mixer to precipitate the proteins and then spun at 1000g
for 30 minutes. The supernatant was collected and acidified
with 20 μΐ of glacial acetic acid and stored at —70 °C.
Further purification of the samples was achieved using C18 Sep-
Pak cartridges. Prior to sample application, each cartridge was
washed sequentially with 2 ml of methanol, 5 ml of water and
2ml of 15 ml/l acetic acid (pH 3.6). The sample -was passed
through the Sep-Pak with a plastic syringe followed by addition
of l ml of 15 ml/l acetic acid (pH 3.6), 2ml of acetonitrile in
0.1 mol/1 acetic acid, volume fraction 0.1 and 0.5 ml of meth-
anol. The internal Standard and indomethacin were eluted from
the cartridge with l .5 ml of methanol and collected for analysis.
Accurate measurement of solvent volumes for the cartridges
was critical, particularly for the methanol elutioin Step, in order
to recover indomethacin and the internal Standard. Loss of
liquid was minimized by laying the cartridge on its side between
washes.
When processing smaller amounts of plasma (e. g. 100 μΐ or 250
μΐ), the amounts of internal Standard, methanol/H2O, vojume
fraction 0.75 used for precipitationj and amounts of glacial
acetic acid were scaled djDwn accordingly. The sample and Sep-
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Pak cartridges were processed äs outlined above except that
the final 1.5 ml of methanol were concentrated either in an
airstream under a fume hood or under vacuum.
In order to completely fill the sample loop, 40 of each
processed sample were injected into the 20 sample loop for
analysis. A mobile phase of 45: 55, 0.1 mol/1 acetic acid :
acetonitrile with a flow rate of l ml/min was used (20). The
sensitivity was set at 0.020 absorbance units füll scale with
detector wavelength at 254 nm.
A calibration curve was derived by plotting the ratio of the
area of the indomethacin peak/area of the internal Standard
peak versus the mg/1 of indomethacin added to each Standard.
The amount of indomethacin in each patient sample was deter-
mined in duplicate from the area ratios obtained.
The recoveries of both indomethacin and the Standard were
calculated by adding the amount present at each calibration
point to a total volume of 1.5 ml of methanol. The area counts
were then compared directly with the area counts obtained in
the 1.5 ml of methanol from Sep-Pak after processing plasma
calibration curve Standards.
The identification of indomethacin and the internal Standard
was verified in the following procedures. Methanol containing
indomethacin and internal Standard was injected into the Chro-
matograph in order to obtain the retention times each day.
Furthermore, during development of the assay, plasma samples
used for calibration curves were diluted with an equal volume
of methanol containing the same concentration of indometha-
cin and internal Standard at each calibration point.
The column was cleaned with acetonitrile at the end of each
day and monthly with tetrahydrofuran. The column was stored
in methanol.
Results
The indomethacin assay was linear for 0.5 ml of
plasma using area ratios for 50 §/1 to 10 mg/1, but
a four point calibration from 0.15 mg/1 to 1.0 mg/1
was used (fig. 1), since the patient levels of indo-
methacin usually feil within this ränge. The assay was
repeated 10 times with a linear calibration, similar to
that in figure l, obtained for the indomethacin level
in 0.5 ml of plasma. The inter-assay coefficients of
Variation at each point in the 10 calibration curves
were: 0.15 mg/1, 8.49%; 0.30 mg/1, 6.48%; 0.50 mg/1,
5.10%; and 1.00 mg/1, 2.22%. The intra-assay coeffi-
cients of Variation at the 4 calibration points for 2
injections each of duplicate points (assay Variation)
and for 10 injections of the same Standard (Integra-
tion Variation) are shown in table l. The recovery of
both indomethacin and Standard was quantitative
(tab. 2). Results of repeat analysis following storage
of samples ät —70 °C for 2 weeks did not väry from
those obtained originally. These results were all ob-
tained using 0.5 ml of plasma and a final elution of
1.5 ml of methanol from the C« Sep-Pak. The assay
was also linear for indomethacin in concentrations
of 0.1 mg/1 tp 10 mg/1 in 0.5 ml of human plasma
using peak heights from a strip chart recorder (data
not shown).
0.1 0.2 0.3 0.4 0.5 0.6
Indomethacin added to
0.7 0.8 0.9 1.0
plasma C m g / l ]
Area ratio of the indomethacin to the internal Standard
versus the concentration of added indomethacin. Each
calibration point was processed in duplicate (dark
circles) äs outlined in the Experimental Section and
plotted äs shown.
Tab. l. Intra-assay coefficients of Variation in the indometha-
cin HPLC assay1)



















*) See Experimental Section for experimental conditions.
2) The mean ± SD of duplicates determined in duplicate tubes
(n = 4) for each concentration was used to calculate the
coefficient of Variation.
3) The mean ± SD of ten analyses (n = 10) of the same tube
for each concentration was used to calculate the coefficient
of Variation.






















1) The same amount of internal Standard (l g) and varying
amounts of indomethacin were added to both 1.5ml of
methanol and 0.5 ml of plasma. The plasma was processed
äs outlined in the Experimental Section. Elution of internal
Standard and indomethacin from Sep-Pak was carried out
with 1.5 ml of methanol. The area counts of internal Stan-
dard and indomethacin recovered in the processed samples
was compared directly with the respective area counts in the
unprocessed methanol.
2) Mean of duplicates.
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The Sep-Pak removed contaminants eluting in the
flushthrough and also just before the internal Stan-
dard. Despite column cleaning, without Sep-Pak pro-
cessing the internal Standard would Start to elute
on the tail of contaminants within 30—50 analyses,
making accurate quantitation increasingly difficult.
The Sep-Pak cartridges improved sensitivity by stabil-
izing the baseline detected by the monitor and inte-
grator. Processing 8 calibration curve samples and 14
patient plasma samples followed by HPLC analyses
required a total of 16 hours.
Preliminary results have indicated that the assay sen-
sitivity (smaller concentrations of indomethacin in
plasma) can be increased by concentrating the final
1.5 ml of methanol 3-5 fold from the Sep-Pak car-
tridge (fig. 2). We have also shown in preliminary
experiments that it is possible to utilize 0.1 ml of
plasma, provided the final 1.5 ml of methanol are
concentrated 3 —5 fold. Processing five different sam-
ples of plasma which did not contain either indo-
methacin or internal Standard indicated that there
Retention time CminJ
Fig. 2. Chromatogram of 0.5 ml of plasma (48 hours after 3
doses of indomethacin at 12 hour intervals) processed
with Sep-Pak äs outlined in the Experimental Section.
The final 1.5 ml of methanol containing the internal
Standard and indomethacin was concentrated about 2
foid. The absorbance (0.020 absorbance units füll scale)
at 254 nm was recorded by the integrator on the ordi-
nate, while peak retention times are recorded in the
abscissa. The internal Standard eluted at 5.66 minutes
with 40 597 area counts, while indomethacin eluted at
7.90 minutes with 5289 area counts (area ratio 0.130,
0.180 mg/1 indomethacin).
were no interfering substances present in the chroma-
togram for these two materials. Processing plasma
which contained either the internal Standard or the
indomethacin indicated that these materials were re-
covered quantitatively from the Sep-Pak cärtridge.
Analysis of methanol containing dndomethacin and
internal Standard yielded the same chromatogram
before (fig. 3) and after passage over the Sep-Pak
cärtridge. Analysis of those plasma samples obtained
from patients prior to administration of indometha-
cin (fig. 4) yielded no indomethaoin (n = 10) com-
pared to samples obtained following indomethacin
therapy. Haemolyzed plasma can be used since no
interfering substances were detected after processing.
The identification of indomethacin and the internal
Standard was verified by both coinjection and dilütion
of the calibration curve samples with an equal volume
of methanol containing the same concentration of
indomethacin and internal Standard at each calibra-
tion point. Analysis by HPLC indicated that the rest
of the peaks in the chromatogram were diluted to
approximately one-half of their initial area counts,
while those of internal Standard and indomethacin
remained the same indicating identity.
Retfrntfon time Cm in J
Fig. 3. Chromatogram of 1.0 g of internal Standard and 0.5
g of indomethacin added to l .5 ml of methanol (corre-
sponding to a plasma calibration point of 1.0 mg/1
indomethacin). The sample was subjected to analysis by
HPLC äs outlined in the Experimental Section without
processing over Sep-Pak. The absorbance (0.020 ab-
sorbance units füll scale) at" 254 nm was recorded by
the integrator on the Ordinate, while peak retention
p times were recorded on the abscissa. The internal Stan-
dard eluted at 5.85 minutes with 23926 area counts,
while indomethacin eluted at 8J35 minutes with 16 528
area counts. * *
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Retention Urne [min]
Fig. 4. Chromatogram of 0.5 ml of indomethacin free plasma
treated with 2.0 g of internal Standard (twice the usual
amount), The sample was processed with Sep-Pak äs
outlined in the Experimental Section. The absorbance
(0.020 absorbance units füll scale) at 254 nm was re-
corded by the integrator on the Ordinate, while peak
retention times were recorded on the abscissa. The inter-
nal Standard eluted at 5.46 minutes with 38721 area
counts. Indomethacin eluted at 7.67 minutes in calibra-
tion curve sample s. There were 1097 area counts associ-
ated with the peak at 7.71.
Discussion
Modifikation of aii HPLC assay for indomethacin
using Sep-Pak has resulted in increased sensitivity,
lengthened column life and improved reproducibility
with less frequent column cleaning. Though the use
of Sep-Pak requires additional time, some sainples
can be processed while others are being analyzed by
HPLC. Thus, the overall tiine involved is not much
longer than that required in other reported assays
which do not utilize Sep-Pak.
To date, we have used this method to analyze 112
samples from 16 patients with patent ductus ar-
teriosus using 10 calibration cürves with 4 points each
performed in duplicate. Patients were treated with
indomethacin several times during the course öf 72
hours. A peak plasma indomethacin level of 0.500
mg/1 usually resulted in closure of the duct (unpub-
lished observations). Reproducibility has been quite
satisfactory and the initial column is still in use.
Fürthermore, since many impurities are removed by
Sep-Pak, the sensitivity of the monitor could be
higher. This would result in even greater sensitivity
since larger area counts would be obtained.
The methanol employed for elution of the Sep-Pak
bound indomethacin and internal Standard can be
concentrated should greater sensitivity be necessary.
Alternatively, indomethacin in äs little äs 100· 1 of
plasma can be assayed with proper adjustment of the
internal Standard and initial reagents followed by a
3 — 5 fold final methanol effluent concentration. Less
methanol could probably be used to elute from the
Sep-Pak followed by less concentration; we are cur-
rently investigating this approach. Decreasing the
plasma volume requirement for analysis is of great
significance for premature infants. The l ml of blood
required to generate 300 — 500 of plasma is equiva-
lent to 2.5% of the circulating blood volume of a
500 g premature infant.
Several other methodological observations appear to
have improved our results. Various concentrations
and combinations of acetic acid, acetonitrile, and
methanol were used for processing the plasma sam-
ples both initially and with Sep-Pak in order to de-
velop the assay. Acidification of the processed plasma
and Sep-Pak cartridge with acetic acid was necessary
in order to quantitatively bind the indomethacin and
the internal Standard to Sep-Pak. In each new lot of
Sep-Pak cartridges utilized, verification was made
that all of the indomethacin and internal Standard
were recovered in 1.5 ml of methanol. Occasionally,
a minor adjustment may be necessary (± 0.2 ml),
depending on the lot of Sep-Pak. The use of such
solvents äs ethyl ether or tetrahydrofuran during the
extraction or elution procedures was avoided since
concentration of these solvents can lead to produc-
tion and accumulation of explosive peroxides. Emul-
sion producing solvents were not utilized. Finally, the
internal Standard, l -(p-flurobenzoyl)-5-methoxy-2-
methylindole acetic acid (20) has a fluorine substi-
tüted for the chlorine present in indomethacin, pro-
viding the internal Standard with properties (molecu-
lar weight, ionic Charge and solubility) similar but
not indentical to indomethacin. This similarity may
have helped in obtaining quantitative recoveries of
both indomethacin and the internal Standard from
Sep-Pak.
Conclusion
In summary, an HPLC assay for indomethacin in
small volumes of plasma has been described utilizing
Sep-Pak for processing samples. The recovery of
indomethacin and the internal Standard was quantita-
tive. As a result, the assay is ideal for both clinical
management äs well äs investigational study of
plasma prostaglandins and their Inhibition in prema-
ture infants. Further, preservation of the column us-
ing Sep-Pak provides a cost benefit which should, in
practical terms, permit more frequent use of this
analytical technique.
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